Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $1,737,000.00 in Stock

17 Jun 2026, 21:13 by Scott Moore · The Cerbat Gem

Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) insider Harlan Robins sold 100,000 shares of the stock in a transaction on Monday, June 15th. The shares were sold at an average price of $17.37, for a total transaction of $1,737,000.00. Following the sale, the insider directly owned 1,412,058 shares of the company’s stock, valued at $24,527,447.46. The trade was a 6.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Adaptive Biotechnologies Stock Down 2.6%

Shares of NASDAQ:ADPT traded down $0.44 on Wednesday, hitting $16.78. The company had a trading volume of 13,515,842 shares, compared to its average volume of 2,445,506. Adaptive Biotechnologies Corporation has a 1 year low of $9.96 and a 1 year high of $20.76. The firm has a market capitalization of $2.69 billion, a price-to-earnings ratio of -50.85 and a beta of 2.15. The firm’s 50-day simple moving average is $14.72 and its two-hundred day simple moving average is $15.59.

Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The company had revenue of $70.87 million during the quarter, compared to analysts’ expectations of $61.03 million. During the same period last year, the company posted ($0.20) EPS. Adaptive Biotechnologies’s revenue was up 35.1% on a year-over-year basis. Equities research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current year.

Hedge Funds Weigh In On Adaptive Biotechnologies

Several hedge funds have recently modified their holdings of ADPT. Caitong International Asset Management Co. Ltd purchased a new position in shares of Adaptive Biotechnologies in the fourth quarter worth $28,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after buying an additional 1,565 shares in the last quarter. KBC Group NV purchased a new position in shares of Adaptive Biotechnologies in the first quarter worth $45,000. Assetmark Inc. lifted its holdings in shares of Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after buying an additional 2,708 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. purchased a new position in shares of Adaptive Biotechnologies in the fourth quarter worth $51,000. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Trending Headlines about Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

Negative Sentiment: Adaptive Biotechnologies priced an upsized $300 million offering of 0% convertible senior notes due 2031, which raises fresh capital but also signals potential dilution risk and added complexity for shareholders. The company plans to use the proceeds to repay the OrbiMed Purchase Agreement, fund capped call transactions, and repurchase $25 million of stock to help offset dilution. Article Title
Negative Sentiment: Multiple insider sales were disclosed, including Chief Scientific Officer Harlan S. Robins selling 100,000 shares and another 6,160 shares under a 10b5-1 plan. While pre-planned, the volume of insider selling may reinforce caution around the stock. Article Title
Neutral Sentiment: BTIG Research reaffirmed its Buy rating and kept a $22 price target, suggesting analysts still see meaningful upside from current levels. Article Title
Neutral Sentiment: The company’s recent earnings trend remains supportive, with Q1 revenue up 35.1% year over year and results beating expectations, which helps offset some of the financing-related concerns.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. TD Cowen raised their price objective on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. JPMorgan Chase & Co. reduced their price target on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. BTIG Research reiterated a “buy” rating and issued a $22.00 price target on shares of Adaptive Biotechnologies in a research note on Wednesday. Wall Street Zen lowered shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, Morgan Stanley reduced their price target on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Adaptive Biotechnologies presently has an average rating of “Moderate Buy” and a consensus target price of $19.57.

Check Out Our Latest Stock Analysis on ADPT

Adaptive Biotechnologies Company Profile

(Get Free Report)

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.